文献速递类风湿关节炎其他结缔组织病

阿巴西普治疗类风湿关节炎相关间质性肺病的进展预测因素:多中心526例队列数据

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究基于全国多中心队列中526例接受阿巴西普治疗的类风湿关节炎患者,纳入343例合并间质性肺病且有系列肺功能检查者。结果显示24个月内23.3%出现间质性肺病进展,既往甲氨蝶呤治疗呈保护作用,既往戈利木单抗暴露和高DAS28-ESR增加进展风险。

要点

  • 阿巴西普治疗下近四分之一RA-ILD患者24个月内仍出现间质性肺病进展。
  • 既往甲氨蝶呤治疗与间质性肺病进展风险降低相关(OR=0.453)。
  • 既往戈利木单抗暴露和高DAS28-ESR与间质性肺病进展风险升高相关。

核心结论

  • 尽管接受阿巴西普治疗,仍有近四分之一的类风湿关节炎相关间质性肺病患者出现间质性肺病进展。
  • 阿巴西普耐受性良好,多数患者肺功能和风湿病情保持稳定。
  • 既往治疗和关节疾病活动度可能有助于预测间质性肺病进展风险。

研究设计与样本

  • 全国多中心研究,从526例接受阿巴西普治疗的类风湿关节炎患者队列中纳入343例合并间质性肺病且具备系列肺功能检查者。

主要发现

  • 80例(23.3%)出现间质性肺病进展,263例(76.7%)肺功能稳定或改善。
  • 进展组基线特征与稳定组相当,但进展组呼吸困难评分更高,既往甲氨蝶呤暴露比例更低(63% vs 76%;p=0.02),既往托珠单抗暴露例数更少(4 vs 34;p=0.048)。
  • 多因素分析显示既往甲氨蝶呤治疗具保护作用(OR=0.453),既往戈利木单抗暴露(OR=10.009)和更高DAS28-ESR值(OR=1.284)增加间质性肺病进展风险。
  • 间质性肺病影像学模式及阿巴西普起始时间未见显著差异。

关键数值与推荐

  • 间质性肺病进展定义为阿巴西普起始后24个月内用力肺活量绝对下降≥10%,或相对下降5-9%并伴临床进展(改良医学研究委员会呼吸困难量表[mMRC])和/或影像学进展(高分辨率计算机断层扫描)。

临床怎么用

  • 对接受阿巴西普治疗的类风湿关节炎相关间质性肺病患者,应评估既往甲氨蝶呤、戈利木单抗暴露史及DAS28-ESR以辅助判断间质性肺病进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify clinical and therapeutic predictors of interstitial lung disease (ILD) progression in patients with RA treated with abatacept (ABA) in clinical practice. METHODS: National multicentre study including 343 RA-associated interstitial lung disease patients from a national cohort of 526 individuals treated with ABA, all of them with serial pulmonary function tests available. Progressive ILD was defined as an absolute decline in forced vital capacity ≥10% or a relative decline of 5-9% combined with clinical progression (modified Medical Research Council Dyspnea Scale [mMRC]) and/or radiological progression (high-resolution computed tomography) over 24 months after starting ABA. A comparative and multivariable analysis was performed to identify factors associated with ILD progression. RESULTS: Progressive ILD occurred in 80 patients (23.3%), while 263 (76.7%) showed a stable or improved pulmonary functional course. Baseline characteristics were comparable between groups, except for higher dyspnoea scores and lower prior exposure to MTX (63% vs 76%; p = 0.02) and tocilizumab (4 vs 34; p = 0.048) among progressive cases. Multivariable analysis showed that prior treatment with MTX had a protective role (OR = 0.453), while previous golimumab exposure (OR = 10.009) and higher DAS28-ESR values (OR = 1.284) increased the risk of ILD progression. Interestingly, no significant differences were observed according to the ILD radiologic pattern or time from ABA initiation. CONCLUSIONS: Despite ABA therapy, progressive ILD occurred in nearly one-quarter of RA patients. ABA showed good tolerability and maintained pulmonary and rheumatologic stability in most cases. However, prior treatments and joint disease activity may help to predict the risk of ILD progression.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Serrano-Combarro A, Atienza-Mateo B, Martín-Gutierrez A, et al. Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients. Rheumatology (Oxford). 2026. PMID: 41548230. doi:10.1093/rheumatology/keag023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。